Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Size Changed, over the years?
In the past few years, there has been significant growth in the market for chronic inflammatory demyelinating polyneuropathy (CIDP). The market, which is expected to stand at $2.10 billion in 2024, is predicted to rise to $2.38 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.4%. Possible reasons behind this growth during the historical period include a rise in the elderly population, improvements made in treatment choices, heightened awareness leading to early detection, progression in immunology and autoimmune research, and an increased occurrence of autoimmune diseases.
How Much Will the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Be Worth in 2029?
Expectations are high for the chronic inflammatory demyelinating polyneuropathy (CIDP) market to experience significant expansion in the coming years. By 2029, the estimated market value will be approximately $3.11 billion, signifying a compound annual growth rate (CAGR) of 8.1%. Key factors contributing to this projected increase include a globally aging population, a renewed interest in studying and treating rare diseases and autoimmune disorders, enhanced access to healthcare services, patient education and advocacy, and improved healthcare facilities. The forecast period is also expected to see a rising incidence of CIDP, novel therapeutic advancements, increased R&D initiatives, the advent of biosimilar therapies, and strides toward personalized medicine approaches.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21144&type=smp
Which is the Largest Company in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Major companies operating in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are Pfizer Inc., Johnson & Johnson, Sanofi SA, Novartis AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Behring (CSL Limited), Grifols S.A., Sun Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Octapharma AG, Cipla Inc., Hikma Pharmaceuticals plc, Halozyme Therapeutics, Hualan Biological Engineering Inc, argenx SE, Hovione, Nihon Pharmaceutical Co. Ltd., Bio Products Laboratory Ltd., AdvaCare Pharma.
What Are the Main Market Drivers in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Industry?
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market growth is anticipated to surge due to escalating healthcare spending. Factors contributing to this increased spending include greater investments in medical facilities, heightened demand for sophisticated treatments, wider insurance provision, and government-led initiatives to improve the accessibility of healthcare. This amplified healthcare expenditure bolsters access to high-tech treatment, timely diagnosis, and improved CIDP management, thereby enhancing patient outcome and life quality. For example, in May 2024, the Office for National Statistics, a government organisation in the UK, reported a rise of 5.6% in nominal healthcare expenditure from 2022 to 2023, reflecting a considerable acceleration compared to the 0.9% growth observed in 2022. Consequently, the surge in healthcare spending is fuelling the growth of the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=21144&type=smp
How Is the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market Segments Structured?
The chronic inflammatory demyelinating polyneuropathy (CIDP) market covered in this report is segmented –
1) By Treatment: Intravenous Immunoglobulin, Corticosteroids, Plasmapheresis, Physiotherapy, Other Treatments
2) By Route Of Administration: Intravenous, Oral, Other Routes Of Administration
3) By Diagnosis: Electrodiagnostic Testing, Nerve Conduction, Electromyography (EMG), Spinal Fluid Analysis, Other Diagnosis
4) By Distribution Channel: Hospitals, Pharmacies, Online Pharmacies, Specialty Clinics
5) By End User: Hospitals, Research Institutions, Homecare Settings
Subsegments:
1) By Intravenous Immunoglobulin (IVIG): Standard IVIG Therapy, High-Dose IVIG Therapy
2) By Corticosteroids: Oral Corticosteroids, Intravenous Corticosteroids
3) By Plasmapheresis: Single-Exchange Plasmapheresis, Multiple-Exchange Plasmapheresis
4) By Physiotherapy: Muscle Strengthening Exercises, Balance And Coordination Therapy
5) By Other Treatments: Immunosuppressive Agents, Monoclonal Antibodies
What Strategic Trends Are Transforming the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
Major firms in the chronic inflammatory demyelinating polyneuropathy (CIDP) market are concentrating on advancing techniques like intravenous immunoglobulin (IVIG) therapy to boost treatment effectiveness, elevate patients’ outcomes, and facilitate more precise and efficient immune control for CIDP management. IVIG therapy, a treatment that infuses concentrated antibodies from healthy donors, helps manage the immune system and decrease inflammation in autoimmune diseases. For example, in January 2024, Takeda Pharmaceutical Company Limited, a biopharmaceutical company based in Japan, received FDA approval for GAMMAGARD LIQUID, an IVIG therapy for adults suffering from CIDP. The approval enables its application as an induction therapy, commencing with a preliminary dose, followed by maintenance doses to aid long-term disease management and enhance neuromuscular function.
Access The Full Report Here:
Which Global Regions Offer the Highest Growth in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Market?
North America was the largest region in the chronic inflammatory demyelinating polyneuropathy (CIDP) market in 2024. The regions covered in the chronic inflammatory demyelinating polyneuropathy (CIDP) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21144
This Report Delivers Insight On:
1. How big is the chronic inflammatory demyelinating polyneuropathy (cidp) market, and how is it changing globally?
2. Who are the major companies in the chronic inflammatory demyelinating polyneuropathy (cidp) market, and how are they performing?
3. What are the key opportunities and risks in the chronic inflammatory demyelinating polyneuropathy (cidp) market right now?
4. Which products or customer segments are growing the most in the chronic inflammatory demyelinating polyneuropathy (cidp) market?
5. What factors are helping or slowing down the growth of the chronic inflammatory demyelinating polyneuropathy (cidp) market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model